A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
Conditions
Relapsing Multiple Sclerosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
INECO Neurociencias Orono, Rosario, Santa Fe Province, Argentina
Sanatorio del Sur S.A., San Miguel de Tucumán, Argentina
L2IP ?Instituto de Pesquisas Clínicas Ltda., Brasília, Federal District, Brazil
Instituto de Neurologia de Curitiba - Hospital Ecoville, Curitiba, Paraná, Brazil
Nucleo de Pesquisa Clinica do Rio Grande do Sul NPCR, Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisas Clinicas - CPCLIN, São Paulo, São Paulo, Brazil
Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), Mexico
Neurociencias Estudios Clinicos S.C., Culiacán, Sinaloa, Mexico
Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Poland
Instytut "Pomnik - Centrum Zdrowia Dziecka", Warsaw, Poland
Centro Clnico Acadmico - Braga, Associao (2CA-Braga), Braga, Portugal
Unidade Local de Saude de Coimbra E P E, Coimbra, Portugal
Hospital Universitario de La Princesa, Madrid, Spain
Hospital Universitario Ramon y Cajal, Madrid, Spain
Hospital Universitario Virgen Macarena, Seville, Spain
UH of State NPC Danulo Halytsky NMU in Lviv CID, Clinic of Neurology and Neurosurgery, Lviv, Ukraine
Study leads
Clinical Trials
Study Director
Hoffmann-La Roche